BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28603093)

  • 1. Role of [
    Ye YF; Wang W; Wang T; Yu J; Geng L; Yu SF; Yan S; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):257-263. PubMed ID: 28603093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
    Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
    J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.
    Detry O; Govaerts L; Deroover A; Vandermeulen M; Meurisse N; Malenga S; Bletard N; Mbendi C; Lamproye A; Honoré P; Meunier P; Delwaide J; Hustinx R
    World J Gastroenterol; 2015 Mar; 21(10):3049-54. PubMed ID: 25780305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
    Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation.
    Hsu CC; Chen CL; Wang CC; Lin CC; Yong CC; Wang SH; Liu YW; Lin TL; Lee WF; Lin YH; Chan YC; Wu YJ; Eng HL; Cheng YF
    Transplantation; 2016 Sep; 100(9):1925-32. PubMed ID: 27306534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee SD; Kim SH; Kim SK; Kim YK; Park SJ
    Transplantation; 2015 Oct; 99(10):2142-9. PubMed ID: 25905981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
    Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
    Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma.
    Kim YK; Kim SH; Lee SD; Lee SA; Park SJ
    Hepatobiliary Pancreat Dis Int; 2014 Jun; 13(3):250-8. PubMed ID: 24919607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Llovet JM; Pavel M; Rimola J; Diaz MA; Colmenero J; Saavedra-Perez D; Fondevila C; Ayuso C; Fuster J; Ginès P; Bruix J; Garcia-Valdecasas JC
    Liver Transpl; 2018 Mar; 24(3):369-379. PubMed ID: 29140601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metabolic indices of
    Bauschke A; Altendorf-Hofmann A; Brückner L; Drescher R; Freesmeyer M; Settmacher U
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1401-1410. PubMed ID: 35451699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT.
    Kim YI; Paeng JC; Cheon GJ; Suh KS; Lee DS; Chung JK; Kang KW
    J Nucl Med; 2016 Jul; 57(7):1045-51. PubMed ID: 26985057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Utility of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Detecting Hepatocellular Carcinoma in Patients Before Liver Transplantation.
    Alotaibi F; Kabbani M; Abaalkhail F; Chorley A; Elbeshbeshy H; Al-Hamoudi W; Alabbad S; Boehnert MU; Alsofayan M; Al-Kattan W; Ahmed B; Broering D; Al Sebayel M; Elsiesy H
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):37-41. PubMed ID: 28260429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.
    Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST
    J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection.
    Court CM; Harlander-Locke MP; Markovic D; French SW; Naini BV; Lu DS; Raman SS; Kaldas FM; Zarrinpar A; Farmer DG; Finn RS; Sadeghi S; Tomlinson JS; Busuttil RW; Agopian VG
    Liver Transpl; 2017 Sep; 23(9):1123-1132. PubMed ID: 28688158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
    Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.